Barcelona-area pediatric hospital contributing clinical expertise in childhood rare diseases, leukaemia, brain imaging, and environmental health research.
Hospital Sant Joan de Déu is a leading pediatric hospital near Barcelona specializing in children's and adolescent healthcare, rare diseases, and childhood cancer research. In the EU research landscape, they contribute deep clinical expertise in pediatric populations — from neonatal brain imaging and ADHD management to childhood leukaemia subtypes and adolescent endocrine disorders. They serve as a clinical partner and data provider in large health consortia, bringing real patient cohorts and translational research capabilities to multi-country projects. Their work bridges clinical care with research, particularly in areas where pediatric data is scarce and hospital access is essential.
Core contributor across ImmunAID (autoimmune disorders with child-adult transition focus), SHARE4RARE (rare disease platform), ERICA (rare disease research coordination), and SPIOMET4HEALTH (adolescent PCOS).
Coordinated CLOSER, their largest funded project (EUR 843,750), focused on childhood leukaemia subtypes and bridging South American-European research.
Contributed to TinyBrains (bio-photonic infant brain imaging for congenital heart defects) and FocusLocus (ADHD management in children).
Participant in ATHLETE, studying how environmental pollutants affect health from pregnancy through adolescence using FAIR data management.
Involved in AICCELERATE (AI-driven hospital care pathways for pediatrics), STARS (patient self-management via eHealth/mHealth), and FocusLocus (gamified ADHD tools).
Contributed to STARS (patient self-management tools for hospitalized and outpatient settings) and SHARE4RARE (collective intelligence platform for rare diseases).
In their earlier H2020 participation (2016-2018), HSJD focused on digital health tools and patient empowerment — eHealth platforms, self-management apps, and open innovation for rare disease communities. From 2019 onward, their work shifted decisively toward disease-specific clinical research: childhood leukaemia subtypes, environmental exposome impacts on children, adolescent endocrine disorders (PCOS), and advanced brain imaging in neonates. This evolution suggests a move from general digital health participation toward deeper, disease-focused translational research where their clinical pediatric expertise is harder to replace.
HSJD is consolidating around translational pediatric research — particularly rare diseases, childhood cancer, and environmental health — positioning them as a go-to clinical partner for child-focused health consortia.
HSJD predominantly joins projects as a third party or participant rather than leading them — only 1 of 11 projects was coordinated. This is typical for a clinical hospital: they provide patient access, clinical data, and domain expertise rather than managing large consortia. With 159 unique partners across 26 countries, they operate within broad European networks, suggesting they are a trusted clinical node that multiple consortium leaders turn to when pediatric populations are needed.
HSJD has collaborated with 159 unique partners across 26 countries, indicating wide European reach. Their CLOSER project also extends to South America, giving them an unusual intercontinental dimension for a pediatric hospital.
HSJD is one of very few European pediatric hospitals with active H2020 involvement spanning rare diseases, childhood oncology, neonatal imaging, and environmental health — all centered on children and adolescents. Their clinical setting means they can offer what most research partners cannot: direct access to pediatric patient cohorts, longitudinal clinical data, and real-world care pathway validation. For any consortium needing a pediatric clinical site in Southern Europe, HSJD is a natural choice with a proven track record across multiple disease areas.
